Related Experiment Video
Updated: Oct 31, 2025
10:32
Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
3.8K
CLINICAL FEATURES AND OUTCOMES OF INFANTS WITH RETINOPATHY OF PREMATURITY WHO FAIL ANTIVASCULAR ENDOTHELIAL GROWTH
Lucy T Xu1, David A Levine, Amy K Hutchinson
1Department of Ophthalmology, Emory Eye Center, Atlanta, Georgia.
Retina (Philadelphia, Pa.)
|June 30, 2021
Summary
Retinopathy of prematurity treatment with intravitreal anti-VEGF agents failed in 11% of eyes. Most failures, including recurrent plus disease and Stage 3, occurred after 50 weeks postmenstrual age but achieved favorable anatomical outcomes.
Area of Science:
- Ophthalmology
- Neonatal Medicine
- Pediatric Medicine
Background:
- Retinopathy of prematurity (ROP) is a leading cause of childhood blindness.
- Intravitreal anti-VEGF agents are a common treatment for ROP.
- Understanding treatment failure is crucial for optimizing ROP management.
Observation:
- A retrospective case series analyzed 211 eyes treated with anti-VEGF for ROP.
- 17 eyes (11%) experienced treatment failure.
- Failure presentations included recurrent plus disease, Stage 3 ROP, and retinal detachment.
Findings:
- Most treatment failures occurred after 50-week postmenstrual age.
- Management strategies included laser, repeat injections, and vitrectomy.
- 18 of 23 failed eyes had follow-up, with 17 achieving retinal reattachment.
Implications:
- ROP treatment failures can manifest late in postmenstrual age.
- Despite failures, favorable anatomical outcomes are achievable with timely intervention.
- Further research into predictors and management of ROP treatment failure is warranted.
